Check-Cap
59 articles about Check-Cap
-
Check-Cap Reports First Quarter 2022 Financial Results and Corporate Update
6/1/2022
Check-Cap Ltd., a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer, announced financial results for the first quarter ended March 31, 2022.
-
Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan
2/7/2022
Check-Cap Ltd. today announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its amended Investigational Device Exemption (IDE) application, enabling initiation of the U.S. pivotal study.
-
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Check-Cap Reports Third Quarter 2021 Financial Results and Corporate Update
11/3/2021
Check-Cap Ltd. today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2021.
-
BioSpace Movers & Shakers: Sept. 3
9/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs
9/1/2021
Check-Cap Ltd., a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer, announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs.
-
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
-
Check-Cap Ltd. Announces $35 Million Registered Direct Offering
6/30/2021
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Company's ordinary shares in a registered direct offering.
-
Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
3/19/2021
Received FDA IDE Approval for Pivotal Study of C-Scan® Company on track to initiate a U.S. pivotal study of C-Scan in late 2021
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Check-Cap Issues Letter to Shareholders
1/27/2021
Check-Cap Ltd., a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, issued the following letter from its chief executive officer, Alex Ovadia to its shareholders and the investment community:
-
Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
11/18/2020
Submitted Investigational Device Exemption (IDE) application to the FDA for Pivotal Study of C-Scan®
-
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
8/6/2020
IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.
-
Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
7/23/2020
Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.
-
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
6/5/2020
Check-Cap Ltd . (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan ® , the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a let
-
Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/27/2020
Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
-
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
5/9/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
4/30/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
4/20/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
4/6/2020
Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.